Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Sales of Investments
Cash received from selling or redeeming investments.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Sales of Investments · Q4 FY2026 · quarter ended Sep 2026
Sales of investments growth accelerates
Q4 FY2026 sales of investments of $422.29M rose 315.0% year over year, ahead of the +0.8% change in trailing-twelve-month sales of investments. Sequentially, it rose 238.7% from the prior quarter. Over 3 fiscal years it compounded at +28.6% a year.
Context
- Sales of investments amounted to 154.2% of revenue in FY2026, up 71.1 pp from a year earlier.
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +315.0% holds above the trailing-twelve-month pace of +0.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2026
- 695.23M USD
- Year-over-year change
- +0.8%
- 4-year CAGR
- +26.6%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 695.23M | +0.8% |
| FY2025 | 2025-09-30 | 689.63M | +55.9% |
| FY2024 | 2024-09-30 | 442.34M | +35.4% |
| FY2023 | 2023-09-30 | 326.72M | +20.7% |
| FY2022 | 2022-09-30 | 270.75M | — |
Sales of Investments vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.8% is the 2nd highest of 4, against a peer median of -16.9%.
- Sales of investments amounts to 154.2% of revenue for ARWR, versus a peer median of 14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.82B USD | +4.9% | +19.7% | 189.3% | |
| LTM Jun 2026 | $1.43B USD | -16.9% | -6.9% | 29.8% | |
| LTM Sep 2026 | $695.23M USD | +0.8% | +28.6% | 154.2% | |
| LTM Mar 2026 | $101.74M USD | — | — | 11040.3% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding ARWR) | — | -16.9% | +6.4% | 14.9% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | (176.49M) | (209.28M) | (609.69M) | 30.11M | (717.13M) |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 120.89M | 78.13M | 73.97M | 63.37M | 68.15M |
| Change in Working Capital | (98.29M) | (51.55M) | 25.09M | (18.24M) | 60.9M |
| Accounts Receivables | 8.85M | 1.41M | 0 | (56.97M) | (3.29M) |
| Inventory | 0 | 0 | 0 | 0 | (9.08M) |
| Accounts Payables | (6.59M) | 33M | (5.54M) | 6.29M | 12.48M |
| Other Working Capital | (100.55M) | (85.96M) | 30.63M | 32.45M | 60.78M |
| Other Non-Cash Items | 7.34M | 16.31M | 29.19M | 80.38M | 289.52M |
| Operating Cash Flow | (136.13M) | (153.89M) | (462.85M) | 179.55M | (271.95M) |
| Capital Expenditures | (52.78M) | (176.74M) | (141.47M) | (22.67M) | (12M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (223.39M) | (246.14M) | (720.95M) | (796.26M) | (1.14B) |
| Sales of Investments | 270.75M | 326.72M | 442.34M | 689.63M | 695.23M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (215M) |
| Investing Cash Flow | (5.42M) | (96.16M) | (420.07M) | (129.29M) | (670.48M) |
| Debt Repayment | 0 | 0 | 392M | (191.37M) | 578.52M |
| Common Stock Issued | 5.19M | 3.05M | 431.65M | 270.37M | 305.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 60M | 250M | 46.87M | (5M) | (107.12M) |
| Financing Cash Flow | 65.19M | 253.05M | 870.52M | 74.01M | 776.82M |
| Effect of Forex Changes | (67K) | (122K) | 4.2M | (401K) | 1.8M |
| Net Change in Cash | (76.43M) | 2.89M | (8.21M) | 123.86M | (163.81M) |
| Free Cash Flow | (188.91M) | (330.63M) | (604.32M) | 156.89M | (283.94M) |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.